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SHORT COMMUNICATION
Trends in mortality from primary liver cancer in England and Wales
1975-92: influence of oral contraceptives
JWF Mant and MP Vessey
Department ofPublic Health and Primarn Care. U-niversity ofOxford, Gibson Building, Radcliffe Infirmary, Oxford OX2 6HE,
UK.
Sumnan Numerous case-control studies have suggested a link between the oral contraceptive pill and liver
cancer. The secular trends in liver cancer mortality rates for England and Wales from 1975 to 1992 were
examined to determine whether an effect of the pill was apparent. Liver cancer mortality has remained
constant in women in the age groups that have had major exposure to the pill.
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Evidence is accumulating from case-control studies of an
association between the use of oral contraceptives and
hepatocellular carcinoma in countries where the incidence of
hepatitis B is low. Table I summarises the ten such studies
exploring this relationship that have been published over the
last decade. With the exception of two studies (WHO, 1989;
Kew et al., 1990), the results point to a link between oral
contraceptives and liver cancer, with risk increasing with
duration of use (Forman et al., 1986; Neuberger et al., 1986;
Yu et al., 1991; Tavani et al., 1993). There is also some
evidence that the effect persists for over 10 years after cessa-
tion of use (Tavani et al., 1993). In contrast to the other
studies, the two which did not demonstrate any association
with liver cancer were both in areas where hepatitis B is
endemic. For example. in Kew et al.'s study of liver cancer in
black South African women, 96% of patients were hepatitis
B positive, compared with 62% of the controls (relative risk
13.5).
Internationally, variations in incidence of and mortality
from primary liver cancer are difficult to interpret because of
changes in classification and variations in diagnostic accuracy
over time and in different parts of the world (Stuver and
Trichopoulos, 1994). The most important aetiological factor
for liver cancer world-wide may well be hepatitis B
(Trichopoulos, 1992). However, in countries where the
incidence of hepatitis B is low and liver cancer is correspon-
dingly rare, it may be that use of the oral contraceptive pill is
an important determinant of liver cancer mortality trends in
women. Since the late 1960s, the contraceptive pill has been
in widespread use in the United Kingdom, to the extent that
over 80% of women born in the UK in the 1950s have had
some experience of it (Villard-Mackintosh et al., 1989;
Thorogood and Vessey, 1990). The possible impact of the pill
on mortality from liver cancer in England and Wales between
1958 and 1981 was explored by Forman et al. (1983) using
national death certification rates. They found that there was
indeed a statistically significant increase in the death rate of
women aged 20-39 from 0.9 to 1.8 per million when com-
panng the death rate from 1970-75 with that from 1976-81.
This increase was not found in men or older women. The
aim of this paper is to review the mortality trends in England
and Wales from primary liver cancer since Forman et al.'s
analysis to observe whether this rise has been sustained.
Materials and metdods
National death certification rates for England and Wales for
the period 1975 to 1992 were examined in 10 year age bands
covering the age range 25-74 for both women and men (to
give a 'control' population). Given the low incidence of the
disease in England and Wales, the rates were aggregated over
3 year periods. The information was obtained from routinely
published national statistics (Office of Population Censuses
and Surveys, 1976-94). The numerator was restricted to
deaths coded as 155.0 by the 8th (for 1975-78) and 9th
(1979-92) revisions- of the ICD codes - 'primary liver
cancer'. Cholangiocarcinoma (155.1) was excluded since the
case-control studies that had suggested a link with oral
contraceptive use were largely concerned with hepatocellular
carcinoma (see Table I). Those that did look for any associa-
tion between the pill and cholangiocarcinoma have been
inconclusive (Forman et al., 1986; WHO, 1989; Hsing et al.,
1992). Cholangiocarcinoma and primary liver cancer are not
separated out in the published cancer incidence data for
England and Wales (OPCS, 1994), nor are they separated out
in published mortality data before 1975. Therefore, the
analysis is restricted to mortality data from 1975 to 1992.
Where a trend was observed, a point estimate for the trend
was made and approximate 95% confidence intervals cal-
culated using a poisson regression model on General Linear
Interactive Modelling (GLIM) software.
Results
Figure 1 shows the age-specific mortality trends for women
from primary liver cancer over the period 1975-92. There
have been no further rises in the death rate from liver cancer
in young women since that observed by Forman et al. (1983).
The rate in women aged 25-34 has stayed at around 1.4 per
million over the study period. Similarly, there has been no
discernible trend in women aged 35-44 or 45-54, with the
annual death rates staying around 2.3 per million and 5.9 per
million respectively. There was a rise in the death rate for
women aged 55-64 from 10 per million in 1975-77 to 15 per
million in 1990-92 (change: 10% rise every 3 years; 95%
confidence interval 5- 15%).
Figure 2 shows the trends for men over the same period.
The death rates are much higher for each age group. There
has been a change in the rate in 65 to 74-year-olds from 55
per million in 1975-77 to 96 per million in 1990-92 (change:
11% every 3 years; 95% confidence interval 8-13%). There
has also been a rise in mortality in the 25 to 34-year-olds,
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Figure 1 Age-specific mortality trends for primary liver cancer in
women in England and Wales. 1975-92. E. 65-74: 0. 55-64;
* 45-54; O. 35-44; A. 25-34.
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Figure 2 Age-specific mortality trends for primary liver cancer in
men in England and Wales 1975-92. *. 65-74; 0. 55-64; *.
45-54; O. 35-44; A. 25-34.
from 1.1 per million in 1975-77 to 2.4 per million in
1990-92 (change: 17% every 3 years; 95% confidence inter-
val 5-31%). The rise in mortality in women aged 55-64 is
not mirrored in men.
Discwss
This review of the mortality trends for primary liver cancer
in England and Wales does not appear to indicate any
substantial impact of use of the oral contraceptive pill.
Among women, only those aged 55-64 experienced any rise
in mortality from liver cancer. It is difficult to attribute this
rise to the oral contraceptive pill: women aged 55-64 in 1984
would have been 31-40 in 1960, when the oral contraceptive
was first available in the United Kingdom. While some of
these women will have taken the oral contraceptive pill,
much greater use will have occurred in younger age groups.
For example. in 1976. 18% of women aged 30-39 were
taking oral contraceptives in the United Kingdom as com-
pared with 37% of 20 to 29-year-olds (Thorogood and
Vessey, 1990).
What rise in mortality would have been anticipated in
England and Wales from the case-control studies? Pooling
of the results of some of the published case-control studies
suggests that the summary relative risk is 2.6 for liver cancer
from ever use of the pill (Prentice. 1991). If 80% of women
in the United Kingdom take the pill at some point in their
lives (Villard-Mackintosh et a!.* 1989). then the rate in
women aged 45-54 might have been expected to have gone
up from 5 per million (rate in 1978-80) to 11 per million.
This has not been observed. While it is inappropriate to
attribute causality (or lack of it) from interpretation of
secular trends. the absence of any observed effect of the
contraceptive pill on mortality from liver cancer in England
and Wales must raise a question mark over the association
between the pill and liver cancer that has been noted in
case-control studies.
How can the discrepancy between the evidence from the
case-control studies and from national vital statistics be
explained? One explanation is that the time trends might be
misleading. Trends based on death certification rates need to
be interpreted with caution. Changes in death certification
practice over time might mask real trends. Liver cancer as a
diagnosis is particularly prone to error. since it is a relatively
rare disease. but can be 'mimicked' by a much commoner
disease, namely metastatic liver disease. Thus. even a minor
change in the accuracy of identifying secondary liver cancer
might have an important knock-on effect on the rate of
primary liver cancer. Furthermore, a rise in incidence will not
be reflected in a rise in mortality if there is a concurrent
improvement in survival. To some extent, the use of men as a
*control' population compensates for these weaknesses since
changes in survival and in diagnostic accuracy are unlikely to
be related to sex (unless the pill was associated with liver
cancer of better prognosis). A second possible explanation is
that exposure to the pill was different in the case-control
studies as compared with the general population. The
association between the pill and liver cancer observed in the
case-control studies was related to duration of use (see
Table I). It might be that 'ever use' in the case-control
studies entailed different exposure (in terms of type of pill
and duration of use) to 'ever use' in the general population.
Thirdly. it is conceivable that the case-control studies were
confounded by a subtle. as yet. unidentified factor associated
with both use of the pill and with liver cancer.
Another source of evidence concerning the relationship
between the contraceptive pill and liver cancer is cohort
studies. However. in the 20 year follow-up of the Oxford
Family Planning Association Study in the United Kingdom.
out of 238 deaths, only one had been from liver cancer, and
this was an angiosarcoma in a woman who had never used
oral contraceptives (Vessey et al.. 1989). In a much larger
study of 166 000 women carried out in the United States, ten
deaths from liver cancer had occurred by the 12th year of
follow-up (Colditz. 1994). Ever use of oral contraception was
not found to be related to risk of liver cancer mortality
(relative risk 0.43. confidence interval 0.08-2.42). It is not
possible to draw any firm conclusions from these cohort
studies because of the low number of deaths from liver
cancer. Nevertheless, they do provide some circumstantial
evidence to question the relationship between the contracep-
tive pill and liver cancer.
Conclusion
The association between the oral contraceptive pill and liver
cancer that has been observed in several case-control studies
has not been reflected in the mortality trends for liver cancer
in women in England and Wales over the last decade. This
finding casts some doubt on the importance of the contracep-
tive pill from a public health perspective as a risk factor for
liver cancer.
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